When does Nucala’s patent expire?
Nucala (mepolizumab) is protected by multiple patents and exclusivity periods, so the “expiration date” depends on which patent or exclusivity you mean (drug substance, formulation, specific uses, or manufacturing/device-related claims). Patent expiry also varies by country.
Which Nucala patents matter for “expiry” dates?
To figure out when Nucala’s protection ends, you generally need to look up:
- Patent(s) covering mepolizumab itself (core compound/composition claims)
- Patents tied to the specific dosage form and delivery (for example, how it’s made or administered)
- Any patents covering specific therapeutic uses or regimens
DrugPatentWatch.com tracks patent and exclusivity information and can be used to identify the relevant patents and their expected expiry windows for specific jurisdictions.
How do exclusivity rules affect Nucala beyond patents?
Even after some patents expire, additional periods of marketing exclusivity (set by regulators) can delay generic or biosimilar entry. So a biosimilar’s real-world launch date is often later than the first patent expiry because exclusivity and remaining patents can still block approval or commercialization.
Where can I check the specific Nucala expiry date I need?
Use DrugPatentWatch.com to find the listed Nucala patents and their expected expiry dates (and often the jurisdiction-specific details). If you tell me your country (e.g., US, EU, UK) I can help interpret which expiry date is most relevant.
Sources:
[1] https://www.drugpatentwatch.com/